Alzheimer's disease

CENTRAL NERVOUS SYSTEM

Porsolt offers models in all areas of psychopharmacology, epilepsy, sleep-wake, and neurodegenerative disorders. We are uniquely placed to offer a full range of CNS efficacy and safety pharmacology assessments, from basic models and regulatory tests, through the evaluation of abuse and dependence liability and proconvulsant risk using EEG.

Alzheimer's disease

Alzheimer’s disease (AD) is one of the major neurodegenerative diseases affecting millions of people worldwide and lacking effective therapeutic intervention.
AD is characterized by memory deficits and rarely by movement impairment.

Alzheimer’s disease

EARLY PHASE

LATE PHASE

Mild cognitive impairment

No clear motor impairments

Dementia in most of cases

No clear motor impairments

In vitro models - Alzheimer’s disease

Hyper-phosphorylation of Tau and aberrant gamma-secretase activity are respectively involved in the formation of intracellular neurofibrillary tangles and in the extracellular deposition of amyloid plaques in the brain – the two hallmarks of Alzheimers’s disease.

Fluofarma , our subsidiary, proposes cell models to identify or characterize compounds targeting Tau phosphorylation cascade or γ-secretase activity.

In vivo models - Alzheimer’s disease

• Streptozotocin (STZ) - induced cognitive deficit.

Although the cause of AD remains unknown, the sporadic form is mainly related to aging and other risk factors such as diabetes and metabolic disturbances.

Intracerebroventricular administration of STZ induces biochemical changes in the brain contributing to the appearance of memory impairments in the rat.

> Suggested approach:  Evaluation of motor coordination by Morris water maze and delayed-alternation test

Dowload our latest posters: